Loading...
Loading...
MEIP| Name | Value |
|---|---|
| Revenues | 5.9M |
| Cost of Revenue | 0.5M |
| Gross Profit | 5.4M |
| Operating Expense | 22.3M |
| Operating I/L | -16.4M |
| Other Income/Expense | 1.0M |
| Interest Income | 1.0M |
| Pretax | -15.4M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | -15.4M |
MEI Pharma, Inc. is a late-stage pharmaceutical company specializing in the development and commercialization of cancer therapies. The company's product pipeline includes Zandelisib, an oral inhibitor in Phase III clinical trial for relapsed/refractory follicular lymphoma, and Voruciclib, an oral inhibitor in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor for human epidermal growth factor receptor 2 negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor for myelodysplastic syndrome. The company has strategic partnerships and collaborations with leading pharmaceutical and biotech companies to advance its innovative treatments.
